- Home
- TWN vs ALDX Comparison
TWN vs ALDX Comparison
Compare TWN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWN
- ALDX
- Stock Information
- Founded
- TWN 1986
- ALDX 2004
- Country
- TWN Hong Kong
- ALDX United States
- Employees
- TWN N/A
- ALDX N/A
- Industry
- TWN Trusts Except Educational Religious and Charitable
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- TWN Finance
- ALDX Health Care
- Exchange
- TWN Nasdaq
- ALDX Nasdaq
- Market Cap
- TWN 346.7M
- ALDX 314.6M
- IPO Year
- TWN N/A
- ALDX 2014
- Fundamental
- Price
- TWN $58.10
- ALDX $5.06
- Analyst Decision
- TWN
- ALDX Strong Buy
- Analyst Count
- TWN 0
- ALDX 2
- Target Price
- TWN N/A
- ALDX $9.50
- AVG Volume (30 Days)
- TWN 20.1K
- ALDX 666.3K
- Earning Date
- TWN 01-01-0001
- ALDX 11-06-2025
- Dividend Yield
- TWN 1.10%
- ALDX N/A
- EPS Growth
- TWN N/A
- ALDX N/A
- EPS
- TWN N/A
- ALDX N/A
- Revenue
- TWN N/A
- ALDX N/A
- Revenue This Year
- TWN N/A
- ALDX N/A
- Revenue Next Year
- TWN N/A
- ALDX $63.48
- P/E Ratio
- TWN N/A
- ALDX N/A
- Revenue Growth
- TWN N/A
- ALDX N/A
- 52 Week Low
- TWN $25.22
- ALDX $1.14
- 52 Week High
- TWN $41.51
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- TWN 71.02
- ALDX 42.47
- Support Level
- TWN $56.10
- ALDX $4.70
- Resistance Level
- TWN $57.00
- ALDX $5.40
- Average True Range (ATR)
- TWN 1.80
- ALDX 0.30
- MACD
- TWN 0.09
- ALDX -0.04
- Stochastic Oscillator
- TWN 90.06
- ALDX 32.82
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.